Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of “Moderate Buy” by Analysts

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has earned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $44.10.

A number of equities research analysts have weighed in on the company. Jefferies Financial Group assumed coverage on Olema Pharmaceuticals in a report on Thursday, March 19th. They issued a “buy” rating and a $40.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 18th. Wolfe Research began coverage on shares of Olema Pharmaceuticals in a research note on Friday, March 27th. They set a “peer perform” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Tuesday, April 21st. Finally, Wall Street Zen raised Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th.

Institutional Investors Weigh In On Olema Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its holdings in shares of Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after acquiring an additional 477 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Olema Pharmaceuticals by 8.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,018 shares of the company’s stock valued at $325,000 after acquiring an additional 987 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Olema Pharmaceuticals by 44.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after acquiring an additional 1,169 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Olema Pharmaceuticals by 9,476.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after acquiring an additional 1,232 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Olema Pharmaceuticals by 13.8% during the 4th quarter. ProShare Advisors LLC now owns 14,367 shares of the company’s stock valued at $359,000 after acquiring an additional 1,740 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Trading Up 2.7%

Shares of OLMA stock opened at $9.44 on Thursday. The stock’s fifty day moving average price is $13.62 and its two-hundred day moving average price is $20.16. The company has a market cap of $824.58 million, a PE ratio of -4.67 and a beta of 1.98. Olema Pharmaceuticals has a fifty-two week low of $3.90 and a fifty-two week high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.52). Equities analysts predict that Olema Pharmaceuticals will post -2.22 EPS for the current fiscal year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.